Cocrystal Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 25, 2024, covers events surrounding the 2024 Annual Meeting of Stockholders held on June 25, 2024, and the subsequent filing of an amendment to the Certificate of Incorporation on June 27, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol COCP.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure changes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on seven proposals at the Annual Meeting. Key outcomes include:
- Board Election: Six directors were elected for one-year terms.
- Capital Structure Reduction: Stockholders approved reducing authorized capital stock from 155 million shares (150M common, 5M preferred) to 101 million shares (100M common, 1M preferred). This amendment became effective on June 27, 2024.
- Officer Liability Limitation: Stockholders voted against an amendment to limit the liability of the Company's officers (4,850,482 votes for vs. 338,219 votes against).
- Executive Compensation Frequency: Stockholders approved voting on executive compensation every three years (2,882,348 votes for every three years vs. 2,221,675 votes for every one year).
- Other Approvals: Ratification of Weinberg & Company as independent auditors and approval of named executive officer compensation were both approved.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, outlook, or specific risks. The primary corporate action noted is the reduction of authorized shares, which may impact future capital raising flexibility. The rejection of the officer liability limitation amendment indicates shareholder preference for maintaining current liability standards for officers.
Investor Verification Checklist
- Verify the effective date of the capital stock reduction (June 27, 2024) and its impact on the Company's ability to issue new shares.
- Review the implications of the shareholder rejection of the officer liability limitation amendment.
- Confirm the new three-year cycle for executive compensation advisory votes.
- Check the definitive proxy statement filed on May 7, 2024, for detailed rationale behind the proposals.